Zacks Research Issues Optimistic Outlook for PBH Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Equities research analysts at Zacks Research raised their Q1 2027 earnings estimates for shares of Prestige Consumer Healthcare in a research note issued on Tuesday, April 22nd. Zacks Research analyst R. Department now forecasts that the company will post earnings of $1.11 per share for the quarter, up from their previous estimate of $1.09. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share.

Several other analysts have also recently commented on the stock. Royal Bank of Canada lifted their price objective on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a "sector perform" rating in a research note on Friday, March 21st. StockNews.com upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Tuesday. Canaccord Genuity Group lifted their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Oppenheimer boosted their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research note on Thursday, February 13th. Finally, DA Davidson boosted their target price on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $93.33.

Prestige Consumer Healthcare Stock Performance

NYSE PBH traded down $0.54 on Friday, hitting $81.39. 68,494 shares of the company's stock traded hands, compared to its average volume of 287,404. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. Prestige Consumer Healthcare has a 1-year low of $62.35 and a 1-year high of $90.04. The firm's 50-day moving average price is $83.46 and its two-hundred day moving average price is $80.73. The firm has a market capitalization of $4.03 billion, a PE ratio of 19.06, a P/E/G ratio of 2.69 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kestra Investment Management LLC acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $27,000. CIBC Private Wealth Group LLC raised its position in shares of Prestige Consumer Healthcare by 48.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after buying an additional 152 shares during the last quarter. Opal Wealth Advisors LLC acquired a new stake in shares of Prestige Consumer Healthcare in the first quarter valued at about $38,000. Headlands Technologies LLC acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $40,000. Finally, McIlrath & Eck LLC raised its position in shares of Prestige Consumer Healthcare by 19.1% in the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock valued at $75,000 after buying an additional 154 shares during the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company's stock, valued at $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.60% of the stock is currently owned by company insiders.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.